Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVR AlloVir	$2.61 +7.4%	$3.06	$7.96 ▼ $24.15	$13.16M	0.63	15,402 shs	33,885 shs
IMVT Immunovant	$17.49 -5.9%	$15.55	$12.72 ▼ $34.47	$3.18B	0.63	1.22 million shs	1.90 million shs
KRYS Krystal Biotech	$147.73 -1.8%	$135.59	$122.80 ▼ $219.34	$4.35B	0.67	287,552 shs	322,915 shs
RGNX REGENXBIO	$8.24 -5.3%	$8.90	$5.04 ▼ $15.36	$436.39M	1.06	925,062 shs	449,245 shs
SGMO Sangamo Therapeutics	$0.48 -4.0%	$0.52	$0.37 ▼ $3.18	$116.58M	1.23	9.07 million shs	6.13 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVR AlloVir	0.00%	-2.80%	-7.95%	-64.68%	-86.79%
IMVT Immunovant	+2.54%	+13.22%	+18.71%	+20.17%	-39.19%
KRYS Krystal Biotech	+1.51%	+7.64%	+9.73%	-11.07%	-25.95%
RGNX REGENXBIO	+0.23%	+3.20%	-6.15%	+32.82%	-31.87%
SGMO Sangamo Therapeutics	+1.63%	-2.31%	+1.83%	-32.27%	+9.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	1.4814 of 5 stars	3.4	0.0	0.0	0.0	2.7	1.7	0.0
KRYS Krystal Biotech	4.6295 of 5 stars	3.5	1.0	0.0	4.7	3.0	3.3	1.9
RGNX REGENXBIO	4.0129 of 5 stars	3.4	1.0	0.0	4.6	1.5	3.3	0.6
SGMO Sangamo Therapeutics	2.698 of 5 stars	3.3	3.0	0.0	0.0	3.8	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVR AlloVir	0.00	N/A	N/A	N/A
IMVT Immunovant	2.82	Moderate Buy	$36.30	107.55% Upside
KRYS Krystal Biotech	3.00	Buy	$213.75	44.69% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	283.80% Upside
SGMO Sangamo Therapeutics	2.67	Moderate Buy	$4.50	837.11% Upside

Current Analyst Ratings Breakdown

Latest IMVT, ALVR, RGNX, KRYS, and SGMO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$18.00
7/9/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$155.00 ➝ $176.00
6/24/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00
6/24/2025	SGMO Sangamo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/9/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
5/16/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$215.00 ➝ $155.00
5/14/2025	SGMO Sangamo Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $5.00
5/7/2025	KRYS Krystal Biotech	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$195.00 ➝ $189.00
5/7/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$219.00 ➝ $219.00
5/6/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00 ➝ $240.00
4/28/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$221.00 ➝ $240.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVR AlloVir	N/A	N/A	N/A	N/A	$29.35 per share	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
KRYS Krystal Biotech	$290.52M	14.70	$4.56 per share	32.43	$32.90 per share	4.49
RGNX REGENXBIO	$83.33M	4.96	N/A	N/A	$5.24 per share	1.57
SGMO Sangamo Therapeutics	$57.80M	1.94	N/A	N/A	$0.11 per share	4.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVR AlloVir	-$190.42M	-$20.23	N/A	∞	N/A	N/A	-71.03%	-61.27%	8/7/2025 (Estimated)
IMVT Immunovant	-$413.84M	-$2.74	0.00	N/A	N/A	N/A	-80.60%	-71.89%	8/5/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.16	33.50	14.66	N/A	37.17%	14.64%	13.28%	8/4/2025 (Estimated)
RGNX REGENXBIO	-$227.10M	-$3.11	0.00	N/A	N/A	-100.62%	-53.29%	-30.84%	8/7/2025 (Estimated)
SGMO Sangamo Therapeutics	-$97.94M	-$0.39	0.00	N/A	N/A	-124.61%	-345.98%	-79.86%	8/5/2025 (Estimated)

Latest IMVT, ALVR, RGNX, KRYS, and SGMO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	RGNX REGENXBIO	-$1.13	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q1 2026	IMVT Immunovant	-$0.69	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	SGMO Sangamo Therapeutics	-$0.07	N/A	N/A	N/A	$31.68 million	N/A
8/4/2025	Q2 2025	KRYS Krystal Biotech	$1.20	N/A	N/A	N/A	$95.42 million	N/A
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
5/12/2025	Q1 2025	SGMO Sangamo Therapeutics	-$0.11	-$0.14	-$0.03	-$0.14	$7.90 million	$6.44 million
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVR AlloVir	N/A	86.78	86.78
IMVT Immunovant	N/A	11.16	11.16
KRYS Krystal Biotech	N/A	9.65	9.27
RGNX REGENXBIO	N/A	2.93	2.93
SGMO Sangamo Therapeutics	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVR AlloVir	66.05%
IMVT Immunovant	47.08%
KRYS Krystal Biotech	86.29%
RGNX REGENXBIO	88.08%
SGMO Sangamo Therapeutics	56.93%

Insider Ownership

Company	Insider Ownership
ALVR AlloVir	32.07%
IMVT Immunovant	1.80%
KRYS Krystal Biotech	13.70%
RGNX REGENXBIO	12.79%
SGMO Sangamo Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVR AlloVir	110	5.04 million	3.43 million	Optionable
IMVT Immunovant	120	171.07 million	167.99 million	Optionable
KRYS Krystal Biotech	210	28.90 million	24.94 million	Optionable
RGNX REGENXBIO	370	50.16 million	43.75 million	Optionable
SGMO Sangamo Therapeutics	480	233.17 million	223.61 million	Optionable

IMVT, ALVR, RGNX, KRYS, and SGMO Headlines

Recent News About These Companies

H.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy Data

July 3, 2025 | msn.com

SGMO - Sangamo Therapeutics Inc Trailing Returns - Morningstar

July 2, 2025 | morningstar.comM

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Morningstar

June 25, 2025 | morningstar.comM

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Business Wire

June 25, 2025 | businesswire.com

Sangamo cues up Fabry gene therapy filing on STAAR data

June 25, 2025 | pharmaphorum.comP

Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

June 24, 2025 | finanznachrichten.de

Sangamo preps FDA application for Fabry gene therapy on heels of phase 1/2 registrational data

June 24, 2025 | fiercebiotech.comF

Sangamo rises after trial data for Fabry disease therapy

June 24, 2025 | msn.com

Sangamo Therapeutics (NASDAQ:SGMO) Given "Buy" Rating at HC Wainwright

June 24, 2025 | marketbeat.com

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

June 24, 2025 | businesswire.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of "Moderate Buy" by Brokerages

June 24, 2025 | marketbeat.com

H.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO)

May 31, 2025 | insidermonkey.com

Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript

May 12, 2025 | seekingalpha.com

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

May 12, 2025 | finance.yahoo.com

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

May 12, 2025 | zacks.com

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

May 12, 2025 | businesswire.com

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

May 12, 2025 | businesswire.com

Sangamo Therapeutics Q1 2025 Earnings Preview

May 12, 2025 | msn.com

Why Sangamo Therapeutics, Inc.’s (SGMO) Stock Is Up 5.70%

May 10, 2025 | aaii.comA

Sangamo Therapeutics Sets Sights on 2026 BLA Filing for Fabry Disease Gene Therapy

May 7, 2025 | precisionmedicineonline.comP

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

May 7, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMVT, ALVR, RGNX, KRYS, and SGMO Company Descriptions

AlloVir NASDAQ:ALVR

$2.61 +0.18 (+7.41%)

As of 07/14/2025

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Immunovant NASDAQ:IMVT

$17.49 -1.10 (-5.92%)

Closing price 04:00 PM Eastern

Extended Trading

$17.60 +0.11 (+0.63%)

As of 07:38 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Krystal Biotech NASDAQ:KRYS

$147.73 -2.68 (-1.78%)

Closing price 04:00 PM Eastern

Extended Trading

$147.79 +0.06 (+0.04%)

As of 06:24 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

REGENXBIO NASDAQ:RGNX

$8.24 -0.46 (-5.29%)

Closing price 04:00 PM Eastern

Extended Trading

$8.24 +0.00 (+0.06%)

As of 04:24 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Sangamo Therapeutics NASDAQ:SGMO

$0.48 -0.02 (-3.96%)

Closing price 04:00 PM Eastern

Extended Trading

$0.48 0.00 (-0.04%)

As of 07:58 PM Eastern

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time